Klebsiella Pneumoniae Infections Market Size, Share, Forecast and Outlook (2023-2030)

<ol>
	<li>Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Snippet by Infection Type</li>
		<li>Snippet by Drug Class</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>Dynamics
	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Advancements in Treatment Options for Managing Klebsiella Pneumoniae Infections</li>
				<li>The Rising Number of Clinical Trials Focused on Addressing Klebsiella Pneumoniae Infections</li>
				<li>Rapid Prediction of Multidrug-Resistant Klebsiella Pneumoniae through Deep Learning Analysis of SERS Spectra</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Limited Treatment Options for KPC-Producing Klebsiella Pneumoniae</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Porter&#39;s Five Force Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Pipeline Analysis</li>
		<li>Patent Analysis</li>
		<li>Russian-Ukraine Conflict Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>By Infection Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Attractiveness Index, By Infection Type</li>
		</ol>
		</li>
		<li>Pneumonia*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>&nbsp;Urinary Tract Infections (UTIs)</li>
		<li>Bloodstream Infections&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Intra-Abdominal Infection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Wound Infections</li>
	</ol>
	</li>
	<li>By Drug Class
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Attractiveness Index, By Drug Class</li>
		</ol>
		</li>
		<li>Beta-Lactams*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
			<li>Clavulanic Acid</li>
			<li>Sulbactam</li>
			<li>Tazobactam</li>
			<li>Avibactam</li>
			<li>Vaborbactam</li>
		</ol>
		</li>
		<li>Aminoglycoside
		<ol>
			<li>Gentamicin</li>
			<li>Tobramycin</li>
			<li>Amikacin</li>
			<li>Streptomycin</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Quinolones
		<ol>
			<li>Ciprofloxacin (Cipro)</li>
			<li>Levofloxacin</li>
			<li>Moxifloxacin</li>
			<li>Ofloxacin</li>
			<li>Norfloxacin</li>
			<li>Gemifloxacin</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Cephalosporins
		<ol>
			<li>Ceftriaxone</li>
			<li>Cefotaxime</li>
		</ol>
		</li>
		<li>Carbapenems
		<ol>
			<li>Imipenem/cilastatin</li>
			<li>Meropenem</li>
			<li>Doripenem</li>
			<li>Ertapenem</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Retail Pharmacies&nbsp;</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Pfizer Inc. *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Novartis AG</li>
		<li>AdvaCare Pharma</li>
		<li>Merck &amp; Co., Inc.</li>
		<li>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</li>
		<li>Teva Pharmaceuticals USA, Inc.</li>
		<li>Aurobindo Pharma Colombia</li>
		<li>Par Pharmaceutical</li>
		<li>AbbVie</li>
		<li>Actavis&nbsp;(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>Appendix
	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2022, 2026 &amp; 2030 (US$ Billion)

Table 2 Global Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2022, 2026 &amp; 2030 (US$ Billion)

Table 3 Global Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Billion)

Table 4 Global Klebsiella Pneumoniae Infections Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Billion)

Table 5 Global Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2022, 2026 &amp; 2030 (US$ Billion)

Table 6 Global Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 7 Global Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2022, 2026 &amp; 2030 (US$ Billion)

Table 8 Global Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 9 Global Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Billion)

Table 10 Global Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 11 Global Klebsiella Pneumoniae Infections Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Billion)

Table 12 Global Klebsiella Pneumoniae Infections Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 14 North America Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 15 North America Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 16 North America Klebsiella Pneumoniae Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 18 South America Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 19 South America Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 South America Klebsiella Pneumoniae Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 22 Europe Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 23 Europe Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 24 Europe Klebsiella Pneumoniae Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 30 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 31 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 32 Pfizer Inc.: Overview

Table 33 Pfizer Inc.: Product Portfolio

Table 34 Pfizer Inc.: Key Developments

Table 35 Novartis AG: Overview

Table 36 Novartis AG: Product Portfolio

Table 37 Novartis AG: Key Developments

Table 38 AdvaCare Pharma: Overview

Table 39 AdvaCare Pharma: Product Portfolio

Table 40 AdvaCare Pharma: Key Developments

Table 41 Merck &amp; Co., Inc.: Overview

Table 42 Merck &amp; Co., Inc.: Product Portfolio

Table 43 Merck &amp; Co., Inc.: Key Developments

Table 44 Ortho-McNeil-Janssen Pharmaceuticals, Inc.: Overview

Table 45 Ortho-McNeil-Janssen Pharmaceuticals, Inc.: Product Portfolio

Table 46 Ortho-McNeil-Janssen Pharmaceuticals, Inc.: Key Developments

Table 47 Teva Pharmaceuticals USA, Inc.: Overview

Table 48 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 49 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 50 Aurobindo Pharma Colombia: Overview

Table 51 Aurobindo Pharma Colombia: Product Portfolio

Table 52 Aurobindo Pharma Colombia: Key Developments

Table 53 Par Pharmaceutical: Overview

Table 54 Par Pharmaceutical: Product Portfolio

Table 55 Par Pharmaceutical: Key Developments

Table 56 AbbVie: Overview

Table 57 AbbVie: Product Portfolio

Table 58 AbbVie: Key Developments

Table 59 Actavis: Overview

Table 60 Actavis: Product Portfolio

Table 61 Actavis: Key Developments

List of Figures

Figure 1 Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 3 Global Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 4 Global Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 5 Global Klebsiella Pneumoniae Infections Market Share, By Region, 2022 &amp; 2030 (%)

Figure 6 Global Klebsiella Pneumoniae Infections Market Y-o-Y Growth, By Infection Type, 2022-2030 (%)

Figure 7 Pneumonia Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 8 Urinary Tract Infections (UTIs) Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 9 Bloodstream Infections Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 10 Intra-Abdominal Infection Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 11 Wound Infections Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 12 Global Klebsiella Pneumoniae Infections Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 13 Beta-Lactams Drug Class in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 14 Aminoglycosides Drug Class in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 15 Quinolones Drug Class in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 16 Cephalosporins Drug Class in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 17 Carbapenems Drug Class in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Klebsiella Pneumoniae Infections Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 20 Retail Pharmacies Distribution Channel in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 21 Online Pharmacies Distribution Channel in Global Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Klebsiella Pneumoniae Infections Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 24 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 25 Europe Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 26 South America Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 27 Middle East and Africa Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 28 North America Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 30 North America Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 31 North America Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 32 North America Klebsiella Pneumoniae Infections Market Share, By Country, 2022 &amp; 2030 (%)

Figure 33 South America Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 34 South America Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 35 South America Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 36 South America Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 37 South America Klebsiella Pneumoniae Infections Market Share, By Country, 2022 &amp; 2030 (%)

Figure 38 Europe Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 39 Europe Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 40 Europe Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 41 Europe Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 42 Europe Klebsiella Pneumoniae Infections Market Share, By Country, 2022 &amp; 2030 (%)

Figure 43 Asia-Pacific Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 44 Asia-Pacific Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 45 Asia-Pacific Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 46 Asia-Pacific Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 47 Asia-Pacific Klebsiella Pneumoniae Infections Market Share, By Country, 2022 &amp; 2030 (%)

Figure 48 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Value, 2021-2030 (US$ Billion)

Figure 49 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Share, By Infection Type, 2022 &amp; 2030 (%)

Figure 50 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Share, By Drug Class, 2022 &amp; 2030 (%)

Figure 51 Middle East &amp; Africa Klebsiella Pneumoniae Infections Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 52 Pfizer Inc.: Financials

Figure 53 Novartis AG: Financials

Figure 54 AdvaCare Pharma: Financials

Figure 55 Merck &amp; Co., Inc.: Financials

Figure 56 Ortho-McNeil-Janssen Pharmaceuticals, Inc.: Financials

Figure 57 Teva Pharmaceuticals USA, Inc.: Financials

Figure 58 Aurobindo Pharma Colombia: Financials

Figure 59 Par Pharmaceutical: Financials

Figure 60 AbbVie: Financials

Figure 61 Actavis: Financials